Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes

International Journal of Cardiology

Volumn 222, Issue , 2016, Pages 548-556

  Deedwania, Prakash C ^a   Pedersen, Terje R ^b   DeMicco, David A ^c   Breazna, Andrei ^c   Betteridge, D John ^d   Hitman, Graham A ^e   Durrington, Paul ^f   Neil, Andrew ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c PFIZER INC   (United States)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cardiovascular disease; Cardiovascular risk prediction; Diabetes; Low density lipoprotein cholesterol; Stroke; Systolic blood pressure

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE PREDISPOSITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DOUBLE BLIND PROCEDURE; FOLLOW UP; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84982794770     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.07.201     Document Type: Article

References (42)

1. [1] Adler, A.I., Stratton, I.M., Neil, H.A., Yudkin, J.S., Matthews, D.R., Cull, C.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:7258 (2000), 412–419.
2. [2] Turner, R.C., Millns, H., Neil, H.A., Stratton, I.M., Manley, S.E., Matthews, D.R., et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316:7134 (1998), 823–828.
3. [3] Lewington, S., Clarke, R., Qizilbash, N., Peto, R., Collins, R., Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:9349 (2002), 1903–1913.
4. [4] Lewington, S., Whitlock, G., Clarke, R., Sherliker, P., Emberson, J., Halsey, J., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370:9602 (2007), 1829–1839.
5. [5] Law, M.R., Morris, J.K., Wald, N.J., Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 338, 2009, b1665.
6. [6] Baigent, C., Keech, A., Kearney, P.M., Blackwell, L., Buck, G., Pollicino, C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:9493 (2005), 1267–1278.
7. [7] Martin, M.J., Hulley, S.B., Browner, W.S., Kuller, L.H., Wentworth, D., Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 2:8513 (1986), 933–936.
8. [8] Abbott, R.D., Wilson, P.W., Kannel, W.B., Castelli, W.P., High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham study. Arteriosclerosis 8:3 (1988), 207–211.
9. [9] Verschuren, W.M., Jacobs, D.R., Bloemberg, B.P., Kromhout, D., Menotti, A., Aravanis, C., et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 274:2 (1995), 131–136.
10. [10] Paciaroni, M., Hennerici, M., Agnelli, G., Bogousslavsky, J., Statins and stroke prevention. Cerebrovasc. Dis. 24:2–3 (2007), 170–182.
11. [11] Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 346:8991–8992 (1995), 1647–1653.
12. [12] Kurth, T., Everett, B.M., Buring, J.E., Kase, C.S., Ridker, P.M., Gaziano, J.M., Lipid levels and the risk of ischemic stroke in women. Neurology 68:8 (2007), 556–562.
13. [13] Haffner, S.M., Lehto, S., Rönnemaa, T., Pyörälä, K., Laakso, M., Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339:4 (1998), 229–234.
14. [14] Waters, D.D., Guyton, J.R., Herrington, D.M., McGowan, M.P., Wenger, N.K., Shear, C., Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. Am. J. Cardiol. 93:2 (2004), 154–158.
15. [15] LaRosa, J.C., Grundy, S.M., Waters, D.D., Shear, C., Barter, P., Fruchart, J.C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352:14 (2005), 1425–1435.
16. [16] Colhoun, H.M., Thomason, M.J., Mackness, M.I., Maton, S.M., Betteridge, D.J., Durrington, P.N., et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet. Med. 19:3 (2002), 201–211.
17. [17] Colhoun, H.M., Betteridge, D.J., Durrington, P.N., Hitman, G.A., Neil, H.A., Livingstone, S.J., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:9435 (2004), 685–696.
18. [18] Pedersen, T.R., Faergeman, O., Kastelein, J.J., Olsson, A.G., Tikkanen, M.J., Holme, I., et al. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. Am. J. Cardiol. 94:6 (2004), 720–724.
19. [19] Pedersen, T.R., Faergeman, O., Kastelein, J.J., Olsson, A.G., Tikkanen, M.J., Holme, I., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294:19 (2005), 2437–2445.
20. [20] Black, H.R., The paradigm has shifted to systolic blood pressure. J. Hum. Hypertens. 18:Suppl. 2 (2004), S3–S7.
21. [21] Kostis, J.B., Breazna, A., Deedwania, P.C., LaRosa, J.C., The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study. J. Clin. Hypertens. 10:5 (2008), 367–376.
22. [22] Vasan, R.S., Larson, M.G., Leip, E.P., Evans, J.C., O'Donnell, C.J., Kannel, W.B., et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N. Engl. J. Med. 345:18 (2001), 1291–1297.
23. [23] Lawes, C.M., Bennett, D.A., Feigin, V.L., Rodgers, A., Blood pressure and stroke: an overview of published reviews. Stroke, 35(4), 2004, 1024.
24. [24] Lv, J., Neal, B., Ehteshami, P., Ninomiya, T., Woodward, M., Rodgers, A., et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med., 9(8), 2012, e1001293.
25. [25] Waters, D.D., LaRosa, J.C., Barter, P., Fruchart, J.C., Gotto, A.M. Jr., Carter, R., et al. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J. Am. Coll. Cardiol. 48:9 (2006), 1793–1799.
26. [26] Hitman, G.A., Colhoun, H., Newman, C., Szarek, M., Betteridge, D.J., Durrington, P.N., et al. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabet. Med. 24:12 (2007), 1313–1321.
27. [27] Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., Lanas, F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet 364:9438 (2004), 937–952.
28. [28] Scandinavian Simvastatin Survival Study Group, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:8934 (1994), 1383–1389.
29. [29] The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339:19 (1998), 1349–1357.
30. [30] Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:9326 (2002), 7–22.
31. [31] Sever, P.S., Dahlöf, B., Poulter, N.R., Wedel, H., Beevers, G., Caulfield, M., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:9364 (2003), 1149–1158.
32. [32] Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:9753 (2010), 1670–1681.
33. [33] Mihaylova, B., Emberson, J., Blackwell, L., Keech, A., Simes, J., Barnes, E.H., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380:9841 (2012), 581–590.
34. [34] Fulcher, J., O'Connell, R., Voysey, M., Emberson, J., Blackwell, L., Mihaylova, B., et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385:9976 (2015), 1397–1405.
35. [35] Koren-Morag, N., Tanne, D., Graff, E., Goldbourt, U., Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry. Arch. Intern. Med. 162:9 (2002), 993–999.
36. [36] Benfante, R., Yano, K., Hwang, L.J., Curb, J.D., Kagan, A., Ross, W., Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men. Implications of shared risk. Stroke 25:4 (1994), 814–820.
37. [37] Amarenco, P., Bogousslavsky, J., Callahan, A. 3rd, Goldstein, L.B., Hennerici, M., Rudolph, A.E., et al. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 355:6 (2006), 549–559.
38. [38] Amarenco, P., Labreuche, J., Lavallée, P., Touboul, P.J., Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35:12 (2004), 2902–2909.
39. [39] Amarenco, P., Goldstein, L.B., Szarek, M., Sillesen, H., Rudolph, A.E., Callahan, A. 3rd, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 38:12 (2007), 3198–3204.
40. [40] Charlton-Menys, V., Betteridge, D.J., Colhoun, H., Fuller, J., France, M., Hitman, G.A., et al. Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 52:2 (2009), 218–225.
41. [41] Iso, H., Jacobs, D.R. Jr., Wentworth, D., Neaton, J.D., Cohen, J.D., Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N. Engl. J. Med. 320:14 (1989), 904–910.
42. [42] Evans, C.E., Mylchreest, S., Charlton-Menys, V., Durrington, P., The role of hydrostatic pressure in foam cell formation upon exposure of macrophages to LDL and oxidized LDL. Atherosclerosis 197:2 (2008), 596–601.